The Experts below are selected from a list of 33 Experts worldwide ranked by ideXlab platform

Kishore M Gadde - One of the best experts on this subject based on the ideXlab platform.

  • clinical utility of phentermine topiramate qsymia combination for the treatment of obesity
    Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2013
    Co-Authors: Jin Hee Shin, Kishore M Gadde
    Abstract:

    Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an Anorexigenic Agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications – seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either Agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.

  • Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
    Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2013
    Co-Authors: Jin Hee Shin, Kishore M Gadde
    Abstract:

    Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an Anorexigenic Agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications – seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either Agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.

Jin Hee Shin - One of the best experts on this subject based on the ideXlab platform.

  • clinical utility of phentermine topiramate qsymia combination for the treatment of obesity
    Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2013
    Co-Authors: Jin Hee Shin, Kishore M Gadde
    Abstract:

    Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an Anorexigenic Agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications – seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either Agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.

  • Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
    Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2013
    Co-Authors: Jin Hee Shin, Kishore M Gadde
    Abstract:

    Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an Anorexigenic Agent, which is approved for the short-term treatment of obesity, while topiramate is approved for nonweight loss indications – seizure disorders and migraine prophylaxis. The amount of weight loss achieved with combination therapy is of a greater magnitude than what could be achieved with either Agent alone. Adverse events that occur with the combination therapy are in line with the known side effect profiles of the constituent drugs; teratogenicity, a slight increase in heart rate, psychiatric and cognitive adverse effects, and metabolic acidosis are concerns.

Celia D. Sladek - One of the best experts on this subject based on the ideXlab platform.

Mahmoud E Salama - One of the best experts on this subject based on the ideXlab platform.

  • Obestatin and l-carnitine as a defensive strategy against fertility disorders induced by obesity in male rats
    Tanta Medical Journal, 2014
    Co-Authors: Magdi A. El-damarawi, Mahmoud E Salama
    Abstract:

    Aim This study was designed to investigate the usage of obestatin (OB) and l-carnitine (LC) as a defensive strategy against fertility disorders induced by obesity in male rats. Materials and methods The study was carried out on 50 male Wistar rats, which were divided into five groups as follows: the control group, untreated obese rats, obese rats treated with OB, obese rats treated with LC, and obese rats treated with both OB and LC. Results The induction of obesity resulted in significant increase in body weight, plasma level of triglyceride, total cholesterol, low-density lipoprotein-cholesterol, and thiobarbituric acid reactive substance as compared with the control group. In addition, it produced significant lower activities of superoxide dismutase, catalase, and glutathione peroxidase antioxidant enzymes (GHP-Px) in testicular tissue. There was reduced plasma testosterone, follicle stimulating hormone, luteinizing hormone, and low-density lipoprotein-cholesterol and decreased sperm count and motility. OB significantly lowers body weight, plasma levels triglyceride, total cholesterol, low--density lipoprotein-cholesterol, and testicular thiobarbituric acid reactive substance level. These changes were coupled with significant increase in antioxidant enzymes activities in testicular tissue with significant increase in testosterone plasma level and sperm count and motility. This was accompanied by insignificant increase in plasma follicle stimulating hormone and luteinizing hormone levels. LC produced similar but better changes in all parameters except body weight. Moreover, the concomitant administration of both OB and LC to obese rats resulted in more improvement in all parameters than that were noticed in group III or IV. Conclusion The results of the study verified the possible combined use of OB and LC as a defensive strategy against fertility disorders induced by obesity. OB has the upper hand as Anorexigenic Agent, whereas LC is superior against obesity as a case of secondary hypogonadism.

Pierre-vladimir Ennezat - One of the best experts on this subject based on the ideXlab platform.

  • Calcifications in benfluorex-induced valve heart disease: a misknown association.
    Cardiology, 2015
    Co-Authors: François Plurien, Patrick Bruneval, Yannick Jobic, Bernard Iung, Pierre-vladimir Ennezat
    Abstract:

    Benfluorex, an Anorexigenic Agent, is recognized to induce noncalcified restrictive valvular regurgitation. We report a well-documented case of a 73-year-old patient who developed heart failure with aortic and mitral regurgitation following benfluorex intake. Echocardiography and peroperative analysis found large mitral annular calcifications and aortic subvalvular calcifications. Pathology confirmed drug-induced valve heart disease (DIVHD). The presence of valvular apparatus calcification should not lead to diagnosis of degenerative valvular disease and a priori preclude the diagnosis of DIVHD.